Acute Mountain Sickness risk from altitude reached and rate of ascent
Every altitude illness calculation starts from the same reference point: sea-level physiology, where barometric pressure is 760 mmHg and the body operates with a wide safety margin between oxygen supply and demand. Understanding this baseline is what makes the drop at altitude meaningful — AMS risk is fundamentally a story of how far, and how fast, a person moves away from it.
Atmospheric pressure falls approximately exponentially with elevation. A commonly used working approximation is PB(h) ≈ 760 × e^(−h/7000), where h is altitude in meters and PB is barometric pressure in mmHg. At sea level this returns 760 mmHg; by 3000m it has fallen to roughly 505 mmHg, and by 5500m to about 340 mmHg — under half of sea-level pressure.
Because the fraction of oxygen in air stays constant at 20.93% all the way to the stratosphere, it is the falling total pressure — not a changing oxygen percentage — that reduces the partial pressure of oxygen available to breathe. Inspired PO2 is calculated as PIO2 = 0.2093 × (PB − 47), where 47 mmHg is subtracted for water vapor pressure saturating the airway at body temperature.
At sea level, PIO2 is about 149 mmHg. By 3500m it has dropped to roughly 100 mmHg — a decline of one-third before a person has done anything except gain elevation.
Oxygen moves from ambient air to mitochondria through a cascade of falling partial pressures: inspired air (PIO2) → alveolar gas (PAO2) → arterial blood (PaO2) → tissue capillaries → mitochondria. At each step, pressure drops further. At sea level this cascade has enormous reserve — arterial saturation stays pinned near the flat top of the oxyhemoglobin dissociation curve (SpO2 97–99%) even during exercise or minor lung disease.
The oxyhemoglobin dissociation curve is sigmoidal, not linear: hemoglobin saturation stays high (>90%) down to a PaO2 of roughly 60 mmHg, then falls steeply below that. This nonlinearity is why sea-level physiology feels so stable — small pressure changes barely move saturation — while at altitude, once PaO2 drops onto the steep part of the curve, further ascent causes disproportionately large SpO2 declines.
Even at sea level, healthy people vary in resting ventilation, hemoglobin concentration, and hypoxic ventilatory response (HVR) — the reflex that increases breathing rate when oxygen falls. These baseline differences matter enormously once altitude is introduced: they are the biological seed of why two equally fit people can climb the same route at the same rate and have completely different outcomes.
This is the central, counterintuitive fact of altitude medicine that later stages return to repeatedly: cardiovascular fitness at sea level does not predict AMS susceptibility. A marathon runner and a sedentary office worker face statistically similar AMS risk at a given altitude and ascent rate — because the limiting factor is hypoxic ventilatory and cerebrovascular response, not aerobic capacity.
The moment a traveler crosses roughly 2500–3000m without a graded acclimatization schedule, the body enters hypobaric hypoxia: reduced oxygen availability due to lower barometric pressure, not lower FiO2. The initial hours are dominated by fast, reflexive compensation — hyperventilation and mild cerebral vasodilation — while the slower, adaptive changes that constitute true acclimatization have not yet had time to occur.
Using PB(h) ≈ 760 × e^(−h/7000): at 2500m, PB is about 540 mmHg and PIO2 ≈ 103 mmHg; at 3500m, PB ≈ 470 mmHg and PIO2 ≈ 89 mmHg; at 5000m, PB ≈ 375 mmHg and PIO2 ≈ 69 mmHg. The 2500–3000m band is clinically significant because it is roughly where AMS incidence begins climbing sharply in unacclimatized travelers — below it, symptomatic AMS is uncommon; above it, incidence rises steeply with altitude and ascent speed.
This is why virtually every major mountain medicine guideline (Wilderness Medical Society, UIAA) anchors ascent-rate advice to the 3000m threshold rather than to sea level: it marks the zone where hypoxic stress starts to outpace normal, fast compensation.
Peripheral chemoreceptors in the carotid bodies detect falling arterial PO2 and drive an immediate increase in minute ventilation — the hypoxic ventilatory response. This begins within minutes of exposure and is the fastest layer of altitude compensation, well before any of the slower renal or hematologic adaptations of true acclimatization (which take days to weeks).
Hyperventilation raises alveolar PO2 by blowing off CO2, partially offsetting the fall in barometric pressure — but it comes at a cost: the resulting respiratory alkalosis (low arterial CO2, high pH) triggers a compensatory bicarbonate diuresis by the kidneys that takes 1–3 days to fully normalize blood pH. Until that renal compensation catches up, ventilation is somewhat self-limited, which is part of why the first 24–48 hours at altitude are the highest-risk window for AMS.
The magnitude of an individual's HVR is largely genetically determined and only weakly trainable — it is the single strongest known physiological correlate of AMS resistance, and it cannot be assessed by sea-level fitness testing.
Hypoxia is a potent cerebral vasodilator: falling PaO2 relaxes cerebral arterioles, increasing cerebral blood flow in an attempt to maintain brain oxygen delivery despite lower arterial content. This vasodilation, combined with a degree of increased capillary permeability, produces mild brain swelling that is now understood to be a normal, usually self-limited part of the acute hypoxic response — not yet pathological AMS.
In most people, this swelling stays within the brain's limited capacity to compensate (via cerebrospinal fluid displacement) and resolves without symptoms as acclimatization proceeds. In susceptible individuals, or when the ascent is too fast for compensation to keep pace, the same process crosses a threshold into the symptomatic headache and malaise that defines clinical AMS — the subject of the next stage.
Six to twelve hours after arrival at a new altitude, the first symptoms of Acute Mountain Sickness typically appear. Headache is the cardinal, near-universal symptom; the diagnosis is formalized using the Lake Louise AMS Score, a self-report questionnaire that has become the international standard in both clinical practice and altitude research since its introduction in 1991 and revision in 2018.
The Lake Louise Score requires headache as a mandatory component, plus self-rated severity (0 = none, 1 = mild, 2 = moderate, 3 = severe) across four additional categories:
• Headache — 0 to 3 • Gastrointestinal symptoms (nausea, vomiting, loss of appetite) — 0 to 3 • Fatigue and/or weakness — 0 to 3 • Dizziness and/or lightheadedness — 0 to 3 • Difficulty sleeping — 0 to 3
Total score ranges 0–15. A diagnosis of AMS requires headache to be present (score ≥1) together with a total score of 3 or more, in the setting of a recent gain in altitude. Conventional severity bands are: 3–5 = mild AMS, 6–9 = moderate AMS, 10–15 = severe AMS — the last of these overlapping clinically with early cerebral involvement.
A headache alone, without any other symptom and a total score under 3, does not meet the Lake Louise definition of AMS — headache is necessary but not sufficient for diagnosis.
AMS headache is thought to result from a combination of hypoxia-driven cerebral vasodilation, mild interstitial brain swelling, and activation of trigeminovascular pain pathways similar to those implicated in migraine — which is part of why AMS headache often has a throbbing, bilateral, exertion-worsened quality. Elevated intracranial pressure from swelling is generally mild in classic AMS; it becomes much more pronounced in the rarer progression to High Altitude Cerebral Edema (HACE), covered in Stage 5.
Sleep disturbance, one of the five scored categories, has its own distinct mechanism: periodic breathing (Cheyne-Stokes respiration) is common at altitude during sleep, as the interplay between hypoxic drive and hypocapnic suppression causes ventilation to cycle between hyperpnea and brief apneas — fragmenting sleep independently of headache severity.
The critical clinical skill in altitude medicine is distinguishing uncomplicated AMS — unpleasant but self-limited — from early signs of HAPE (High Altitude Pulmonary Edema) or HACE (High Altitude Cerebral Edema), which are medical emergencies. Ataxia (loss of coordinated gait, tested by having the person walk heel-to-toe), altered mental status, and severe unrelenting headache unresponsive to simple analgesia all signal probable HACE rather than simple AMS. Dyspnea at rest, cough, and reduced exercise tolerance disproportionate to fatigue point toward HAPE.
The practical rule used in the field: AMS symptoms should not include ataxia or altered consciousness. Any hint of either mandates treating the case as HACE until proven otherwise, with immediate descent rather than watchful waiting — the risk asymmetry strongly favors overreacting to neurological signs.
Altitude reached matters, but the rate at which it is gained matters just as much — arguably more, since it determines how much time the body has to invoke slower acclimatization mechanisms before hypoxic stress accumulates. Ascent-rate guidelines are the single most actionable, evidence-based tool for reducing AMS risk, and they are dramatically more effective than any pharmacologic intervention alone.
Three simple rules, repeated across nearly every wilderness and expedition medicine guideline, account for most preventable AMS:
1. Climb high, sleep low — a day's highest point can exceed the guideline rate if the group descends to sleep at a lower, previously-tolerated altitude; it is the sleeping altitude, not the peak daytime altitude, that drives acclimatization stress. 2. If symptomatic, do not ascend further — even mild AMS is a signal to hold altitude (rest a day) rather than continue upward; ascending through symptoms is the single strongest modifiable risk factor for progression to HACE/HAPE. 3. If symptoms worsen at rest, descend — a several-hundred-meter descent is often enough to reverse early AMS; the decision to descend should never be delayed to "see if it passes" once moderate-severe symptoms or any neurological sign appears.
These three rules have no cost, require no equipment, and reduce AMS incidence more reliably than any medication — yet they are also the rules most commonly ignored under time or itinerary pressure.
Standard guidance (Wilderness Medical Society) recommends that once above roughly 3000m, sleeping altitude should increase by no more than 300–500 m per night, with an additional full rest day (no net altitude gain) built in for every 1000m of cumulative elevation gained. Below 3000m the tissue is generally more forgiving of faster gains, since PIO2 has not yet fallen into the steep, symptom-prone range described in Stage 2.
This produces a simple planning heuristic: a trek intending to reach 5000m from a 2500m starting point needs roughly (5000−3000)/400 ≈ 5 sleeping-altitude increments plus 2 rest days — on the order of a week, not a weekend, for anything approaching a low-risk itinerary.
Acetazolamide (Diamox), a carbonic anhydrase inhibitor, is the best-studied AMS prophylactic drug. By inducing a mild metabolic acidosis, it accelerates the same compensatory hyperventilation the body would otherwise achieve only gradually over 1–3 days — effectively pre-loading part of the acclimatization process pharmacologically. Typical prophylactic dosing is 125 mg twice daily, started the day before ascent and continued for the first 2–3 days at the new altitude, or throughout continued ascent.
Clinical trials show acetazolamide prophylaxis reduces AMS incidence by roughly 50–75% relative to placebo at a matched ascent profile. It is not a substitute for a sensible ascent schedule — it is best used alongside graded ascent when logistics (flight into a high-altitude airport, fixed itinerary) prevent a fully graded profile, and it does not eliminate risk of HAPE or HACE.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Rapid Ascent | Flight or drive directly to >3500m within <24h | No time for renal/hyperventilatory acclimatization before hypoxic stress accumulates | ~50–85% AMS incidence — use only when unavoidable, ideally with acetazolamide |
| Standard Trekking Pace | ~300–500 m/day sleeping-altitude gain, occasional rest day | Matches guideline rate; renal bicarbonate compensation mostly keeps pace with ascent | ~15–30% AMS incidence — default recommendation for most trekkers |
| Climb High, Sleep Low | Day hikes above camp altitude, descend to sleep lower | Stimulates acclimatization at peak altitude while limiting sleeping-altitude hypoxic exposure | ~10–20% AMS incidence — gold-standard mountaineering technique |
| Pre-Acclimatization | Altitude tent / hypoxic training 2–4 weeks before departure | Induces early ventilatory and hematologic adaptation before ever leaving sea level | ~5–15% AMS incidence — used by expeditions and military units on fixed timelines |
Every case of AMS resolves along one of two paths. In the large majority, holding altitude and resting for 1–3 days is enough for acclimatization to catch up and symptoms to resolve completely. In a much smaller but medically critical minority — especially when ascent continues despite symptoms — the same process can progress into HAPE or HACE, life-threatening altitude illnesses that require immediate descent and, often, supplemental oxygen or definitive treatment.
Path A — safe resolution: the climber holds their current altitude (or descends slightly), rests, hydrates, and optionally takes acetazolamide or symptomatic analgesia. The Lake Louise Score typically falls toward zero over 24–72 hours as renal and ventilatory acclimatization catch up with the hypoxic stimulus. This is the outcome for the large majority of mild-to-moderate AMS cases.
Path B — progression: the climber continues ascending despite a persistently elevated or worsening score, denying or minimizing symptoms ("summit fever" is a recognized behavioral risk factor). Without the time for compensation to catch up, cerebral or pulmonary edema can cross from the mild, near-universal swelling of Stage 2 into frank pathological edema — HACE or HAPE — over a timeframe as short as several hours to a day.
The single decision that separates these two paths in the majority of cases is simple: stop ascending — or better, descend — as soon as symptoms appear, rather than after they worsen.
HACE (High Altitude Cerebral Edema) presents with ataxia — the hallmark sign — plus severe headache, confusion, and in advanced cases altered consciousness progressing to coma. It reflects a crossing from the mild interstitial brain swelling universal at altitude into frank vasogenic edema raising intracranial pressure meaningfully. Immediate descent of at least 500–1000m, supplemental oxygen, and dexamethasone are first-line treatment; untreated, mortality has historically been reported as high as 40%.
HAPE (High Altitude Pulmonary Edema) presents with dyspnea at rest, dry cough progressing to pink frothy sputum, reduced exercise tolerance out of proportion to fatigue, and crackles on lung auscultation. It results from exaggerated, uneven hypoxic pulmonary vasoconstriction that raises pulmonary capillary pressure and drives fluid into the alveoli. Descent, supplemental oxygen, and nifedipine (or a portable hyperbaric bag if descent is impossible) are the standard response — both conditions are medical emergencies where descent is definitive treatment, not just supportive care.
One of the most counterintuitive and clinically important facts in altitude medicine is that AMS susceptibility does not correlate with cardiovascular fitness or age. Susceptibility is instead driven largely by an individual's hypoxic ventilatory response strength, cerebral vascular reactivity, and — most predictive of all — prior personal history of AMS, which raises recurrence risk roughly threefold on a subsequent, similarly-paced ascent regardless of training in between.
Other recognized risk factors include a fast personal ascent rate relative to one's own history, permanent residence at low altitude, and, in some studies, younger age and higher exertion at altitude. Because susceptibility is substantially fixed and hard to predict in advance for a first-time high-altitude traveler, the practical implication is the same one this whole framework has built toward: since who will get sick can't be reliably predicted beforehand, everyone should ascend as though they might be susceptible — which is exactly what graded ascent-rate guidelines are designed to protect.